Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality
Open accessAbstract
CONTEXT: Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer. OBJECTIVE: To estimate risk and mortality reduction stratified by mutation and prior cancer status. DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008. The study was conducted at 22 clinical and research genetics centers in Europe and North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. The women were followed up until the end of 2009. MAIN OUTCOMES MEASURES: Breast and ovarian cancer risk, cancer-specific mortality, and overall mortality. RESULTS: No breast cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372 diagnosed with breast cancer who did not have risk-reducing mastectomy. Compared with women who did not undergo risk-reducing salpingo-oophorectomy, women who underwent salpingo-oophorectomy had a lower risk of ovarian cancer, including those with prior breast cancer (6% vs 1%, respectively; hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.04-0.59) and those without prior breast cancer (6% vs 2%; HR, 0.28 [95% CI, 0.12-0.69]), and a lower risk of first diagnosis of breast cancer in BRCA1 mutation carriers (20% vs 14%; HR, 0.63 [95% CI, 0.41-0.96]) and BRCA2 mutation carriers (23% vs 7%; HR, 0.36 [95% CI, 0.16-0.82]). Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs 3%; HR, 0.40 [95% CI, 0.26-0.61]), breast cancer-specific mortality (6% vs 2%; HR, 0.44 [95% CI, 0.26-0.76]), and ovarian cancer-specific mortality (3% vs 0.4%; HR, 0.21 [95% CI, 0.06-0.80]). CONCLUSIONS: Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a prospective multicenter cohort of 2,482 women with BRCA1 or BRCA2 mutations, among women without prior breast cancer, those who underwent risk-reducing BSO had a lower risk of first breast cancer diagnosis compared with those who did not: 7% versus 23% in BRCA2 carriers (HR 0.36, 95% CI 0.16-0.82) and 14% versus 20% in BRCA1 carriers (HR 0.63, 95% CI 0.41-0.96).
“Among women without a prior history of breast cancer, those who underwent risk-reducing BSO had a lower risk of first breast cancer diagnosis compared with those who did not: 7% versus 23% in BRCA2 carriers (HR: 0.36 (95% CI: 0.16 - 0.82)) and 14% versus 20% in BRCA1 carriers (HR: 0.63 (95% CI: 0.41 - 0.96)).”
From Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of <i>BRCA1</i> or <i>BRCA2</i> Pathogenic Variants (2026) · cites this paper as [54]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredIn that cohort, BSO was associated with reduced breast cancer-specific mortality (2% vs 6%; HR 0.44, 95% CI 0.26-0.76).
“BSO was also associated with reduced breast cancer-specific mortality (2% vs. 6%; HR: 0.44 (95% CI: 0.26 - 0.76))”
From Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of <i>BRCA1</i> or <i>BRCA2</i> Pathogenic Variants (2026) · cites this paper as [54]
The Results section, under “Effect of RRSO on Mortality (Table 4),” reports lower breast cancer-specific mortality after risk-reducing salpingo-oophorectomy (BSO), with the stated HR of 0.44 and 95% CI of 0.26–0.76. The passages in our copy do not report the claimed 2% versus 6% breast cancer-specific mortality figures, so those percentages remain unsupported. (LLM, conf=0.87)
Experimental — accuracy not yet measuredIn that cohort, BSO was associated with lower ovarian cancer-specific mortality (0.4% vs 3%; HR 0.21, 95% CI 0.06-0.80).
“lower ovarian cancer-specific mortality (0.4% vs. 3%; HR: 0.21 (95% CI: 0.06 - 0.80))”
From Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of <i>BRCA1</i> or <i>BRCA2</i> Pathogenic Variants (2026) · cites this paper as [54]
The Results section, under “Effect of RRSO on Mortality (Table 4),” reports an association between risk-reducing salpingo-oophorectomy (BSO) and lower ovarian cancer-specific mortality. It gives HR 0.24 (95% CI 0.08–0.73), however, not the cited HR 0.21 (0.06–0.80); the cited 0.4% versus 3% comparison is not supported by the passages found in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredIn that cohort, BSO was associated with decreased all-cause mortality (3% vs 10%; HR 0.40, 95% CI 0.26-0.61).
“and decreased all-cause mortality (3% vs. 10%; HR: 0.40 (95% CI: 0.26 - 0.61))”
From Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of <i>BRCA1</i> or <i>BRCA2</i> Pathogenic Variants (2026) · cites this paper as [54]
Risk-reducing bilateral salpingo-oophorectomy lowers the likelihood of ovarian and breast cancer among women who carry BRCA1 or BRCA2 gene mutations.
“Risk-reducing bilateral salpingo-oophorectomy (RRSO) lowers the likelihood of ovarian and breast cancer among women who carry BRCA1 or BRCA2 gene mutations”
From Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine (2024) · cites this paper as [1]
The analyses corrected for prophylactic measures, although the effect on contralateral breast cancer prevention was not an endpoint in the article.
“In the analyses we corrected for prophylactic measures, although the effect on CBC prevention 49,50 was not an end point in this article.”
From Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers (2016) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766 · see citing works
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,653 · see citing works
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S. E., Leach, M. O., Lehman, C. D., Morris, E. A., Pisano, E. D., Schnall, M. D., Sener, S. F., et al. (2007) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,632 · see citing works
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399 · see citing works
Breast and Ovarian Cancer Risks Due to Inherited Mutations in <i>BRCA1</i> and <i>BRCA2</i>
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229 · see citing works
Meta-Analysis of <i>BRCA1</i> and <i>BRCA2</i> Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802 · see citing works
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · see citing works
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Veer, L. V., Garber, J. E., Evans, D. G., Isaacs, C. J., Daly, M. B., Matloff, E. T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,462 · see citing works
Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M. L., Hudis, C. A., Ellis, N. A., Boyd, J. A., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,250 · see citing works
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171 · see citing works
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · cited 1× · see citing works
“Risk-reducing mastectomy is a highly effective strategy for breast cancer risk reduction.(20,21) In our prospec-”
Lakhani, S., van de Vijver, M., Jacquemier, J., Anderson, T., Osin, P., McGuffog, L., & Easton, D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 888 · see citing works
Rocca, W. A., Bower, J. H., Maraganore, D. M., Ahlskog, J. E., Grossardt, B. R., de Andrade, M., & Melton, L. J. (2007) · Neurology · doi:10.1212/01.wnl.0000276984.19542.e6 · Cited by 827 · see citing works
Estrogen Therapy and Coronary-Artery Calcification
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071513 · Cited by 711 · see citing works
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670 · see citing works
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., Shoupe, D., Berek, J. S., Hankinson, S., & Manson, J. E. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181a11c64 · Cited by 640 · see citing works
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 620 · see citing works
Anglian Breast Cancer Study Group (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 602 · see citing works
Finch, A. (2006) · JAMA · doi:10.1001/jama.296.2.185 · Cited by 601 · see citing works
Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C. J., Evans, D. G., Lynch, H. T., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 586 · see citing works
Self-citationSurvival patterns after oophorectomy in premenopausal women: a population-based cohort study
Rocca, W. A., Grossardt, B. R., de Andrade, M., Malkasian, G. D., & Melton, L. J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70869-5 · Cited by 548 · see citing works
Eisen, A. F., Lubiński, J., Klijn, J. G. M., Møller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 442 · see citing works
Rebbeck, T. R., Friebel, T. M., Wagner, T. M., Lynch, H. T., Garber, J. E., Daly, M. B., Isaacs, C. J., Olopade, O. I., Neuhausen, S. L., Veer, L. V. ‘., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.8151 · Cited by 412 · see citing works
Self-citationFisher, B., Jeong, J., Bryant, J., Anderson, S., Dignam, J. J., Fisher, E. R., & Wolmark, N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16981-x · Cited by 358 · see citing works
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340 · see citing works
Domchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T. M., Evans, D. G., Isaacs, C. J., Garber, J. E., Daly, M. B., Eeles, R. A., Matloff, E. T., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70585-x · Cited by 327 · see citing works
Self-citationIncreased risk of parkinsonism in women who underwent oophorectomy before menopause
Rocca, W. A., Bower, J. H., Maraganore, D. M., Ahlskog, J. E., Grossardt, B. R., de Andrade, M., & Melton, L. J. (2007) · Neurology · doi:10.1212/01.wnl.0000280573.30975.6a · Cited by 308 · see citing works
Davidson, N. E., O’Neill, A., Vukov, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.551 · Cited by 227 · see citing works
Effect of Bilateral Oophorectomy on Women's Long-Term Health
Parker, W. H., Jacoby, V., Shoupe, D., & Rocca, W. (2009) · Women's Health · doi:10.2217/whe.09.42 · Cited by 161 · see citing works
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan, J. M., Boyd, J. A., Kauff, N. D., Robson, M. E., Scheuer, L., Narod, S. A., & Offit, K. (2002) · PubMed · Cited by 152 · see citing works
Kramer, J. L., Velazquez, I. A., Chen, B. E., Rosenberg, P. S., Struewing, J. P., & Greene, M. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9199 · Cited by 135 · see citing works
Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
Kauff, N. D., & Barakat, R. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3449 · Cited by 133 · see citing works
Rutter, J. L., Wacholder, S., Chetrit, A., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.14.1072 · Cited by 100 · see citing works
Chang-Claude, J. C., Andrieu, N., Rookus, M. A., Brohet, R. M., Antoniou, A. C., Peock, S., Davidson, R., Izatt, L., Cole, T. R. P., Noguès, C., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0829 · Cited by 88 · see citing works
Risk reducing mastectomy: outcomes in 10 European centres
Evans, D. G., Baildam, A. D., Anderson, E. D. C., Brain, A., Shenton, A., Vasen, H. F. A., Eccles, D., Lucassen, A., Pichert, G., Hamed, H., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.062232 · Cited by 86 · see citing works
Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation
Klaren, H. M., Veer, L. J. V., van Leeuwen, F. E., & Rookus, M. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.941 · Cited by 78 · see citing works
Available, N. A. N. (2004) · The Women s Oncology Review · doi:10.1080/14733400400013030 · Cited by 76 · see citing works
Prophylactic Mastectomy for BRCA1/2 Carriers: Progress and More Questions
Hartmann, L. C., Degnim, A. C., & Schaid, D. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.925 · Cited by 55 · see citing works
Shah, P. D., Rosen, M. A., Stopfer, J. E., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0475-1 · Cited by 33 · see citing works
Oophorectomy and cardiovascular mortality
Parker, W. H., & Manson, J. E. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31818d64d6 · Cited by 32 · see citing works
Edlich, R. F., Winters, K. L., Faulkner, B. C., et al. (2006) · Journal of Long-Term Effects of Medical Implants · doi:10.1615/jlongtermeffmedimplants.v16.i4.40 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ludwig, K. K., Neuner, J., Butler, A., Geurts, J. L., & Kong, A. L. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.06.010 · Cited by 243 · see citing works
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104 · see citing works
EMBRACE, Rebbeck, T. R., HEBON, Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., Apostolou, P., Arnold, N., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0768-3 · Cited by 71 · see citing works
Self-citationOverview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe
Marmolejo, D. H., Wong, M. Y. Z., Bajalica-Lagercrantz, S., Tischkowitz, M., Balmaña, J., Patócs, A. B., Chappuis, P., Colas, C., Genuardi, M., Haanpää, M., et al. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104350 · Cited by 67 · see citing works
Looking different, feeling different: women’s reactions to risk-reducing breast and ovarian surgery
kConFab Psychosocial Group on behalf of the kConFab Investigators, Hallowell, N., Baylock, B., Heiniger, L., Butow, P. N., Patel, D., Meiser, B., Saunders, C., & Price, M. A. (2012) · Familial Cancer · doi:10.1007/s10689-011-9504-4 · Cited by 66 · see citing works
D'Alonzo, M., Piva, E., Pecchio, S., Liberale, V., Modaffari, P., Ponzone, R., & Biglia, N. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.015 · Cited by 41 · see citing works
Vencken, P. M. L. H., Kriege, M., Hooning, M., Menke‐Pluymers, M. B., Heemskerk‐Gerritsen, B. A. M., van Doorn, L. C., Collée, M. M., Jager, A., van Montfort, C., Burger, C. W., et al. (2013) · Cancer · doi:10.1002/cncr.27839 · Cited by 40 · see citing works
AlHilli, M. M., & Al-Hilli, Z. (2019) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2018.09.767 · Cited by 15 · see citing works
Metcalf, C. A., Page, C. E., Stocker, B. O. S., Johnson, R. L., Duffy, K. A., Sammel, M. D., Loughead, J., & Epperson, C. N. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.689 · Cited by 7 · see citing works
Abdel-Razeq, H., & Mansour, R. (2026) · World Journal of Oncology · doi:10.14740/wjon2692
- Authors
- Domchek, S. M.
- Affiliations
- Abramson Cancer Center (US)
- Corresponding author
- Domchek, Susan M.
- ORCID
- Domchek, Susan M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-09-01
- Volume
- 304
- Issue
- 9
- Pages
- 967
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC2948529
- OpenAlex
- W2117576401
- Cited by
- 1,494
- References
- 41
- Citations by year
- 2026: 68 · 2025: 67 · 2024: 87 · 2023: 91 · 2022: 61 · 2021: 95 · 2020: 109 · 2019: 120 · 2018: 102 · 2017: 125 · 2016: 116 · 2015: 91 · 2014: 103 · 2013: 80 · 2012: 82
- FWCI
- 46.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research UK (A7357, C5047/A7357)
- National Institutes of Health (1rc4ca153828-01)
- U.S. Public Health Service (HHSN21620074400C)
- National Cancer Institute (R01-CA83855, R01CA083855, RC4-CA153828, N01 CN6700, P30-CA51008-15, R01CA102776, P30-CA16042, P50CA089393, P30CA051008, P30CA016042, P30 CA51008-12)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- BRCA1 mutation carriers, BRCA2 mutation carriers, prophylactic surgery, prophylactic mastectomy, salpingo-oophorectomy, breast cancer risk, ovarian cancer risk, cancer-specific mortality, all-cause mortality, risk stratification, risk communication
- MeSH terms
- Adolescent, Adult, Aged, Breast Neoplasms, Cause of Death, Fallopian Tubes, Female, Genetic Testing, Humans, Mastectomy, Middle Aged, Mutation, Ovarian Neoplasms, Ovariectomy, Prospective Studies, Risk, Genes, BRCA1, Genetic Predisposition to Disease, Genes, BRCA2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
